Published in PLoS One on January 28, 2011
Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2. J Virol (2011) 1.04
Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol (2013) 1.01
Autophagy-inducing protein beclin-1 in dendritic cells regulates CD4 T cell responses and disease severity during respiratory syncytial virus infection. J Immunol (2013) 0.96
Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses. J Virol (2013) 0.92
Response to infections in patients with asthma and atopic disease: an epiphenomenon or reflection of host susceptibility? J Allergy Clin Immunol (2012) 0.92
Limited type I interferons and plasmacytoid dendritic cells during neonatal respiratory syncytial virus infection permit immunopathogenesis upon reinfection. J Virol (2014) 0.87
Differential roles of lung dendritic cell subsets against respiratory virus infection. Immune Netw (2014) 0.85
Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells. Leukemia (2015) 0.82
Respiratory syncytial virus induced type I IFN production by pDC is regulated by RSV-infected airway epithelial cells, RSV-exposed monocytes and virus specific antibodies. PLoS One (2013) 0.82
Pathogen recognition receptor crosstalk in respiratory syncytial virus sensing: a host and cell type perspective. Trends Microbiol (2013) 0.82
Paramyxovirus activation and inhibition of innate immune responses. J Mol Biol (2013) 0.81
Central role of dendritic cells in shaping the adaptive immune response during respiratory syncytial virus infection. Future Virol (2011) 0.81
Role of plasmacytoid dendritic cell subsets in allergic asthma. Allergy (2013) 0.80
Differential response of BDCA-1+ and BDCA-3+ myeloid dendritic cells to respiratory syncytial virus infection. Respir Res (2013) 0.78
Priming of the Respiratory Tract with Immunobiotic Lactobacillus plantarum Limits Infection of Alveolar Macrophages with Recombinant Pneumonia Virus of Mice (rK2-PVM). J Virol (2015) 0.78
Respiratory Syncytial Virus and Cellular Stress Responses: Impact on Replication and Physiopathology. Viruses (2016) 0.77
Dendritic cells in human Pneumovirus and Metapneumovirus infections. Viruses (2013) 0.76
Paramyxovirus infection regulates T cell responses by BDCA-1+ and BDCA-3+ myeloid dendritic cells. PLoS One (2014) 0.76
Effect of chronic morphine administration on circulating dendritic cells in SIV-infected rhesus macaques. J Neuroimmunol (2016) 0.75
CD1(-) and CD1(+) porcine blood dendritic cells are enriched for the orthologues of the two major mammalian conventional subsets. Sci Rep (2017) 0.75
Dysregulation of myelopoiesis by chronic alcohol administration during early SIV infection of rhesus macaques. Alcohol Clin Exp Res (2014) 0.75
Impact of tobacco smoke on upper airway dendritic cell accumulation and regulation by sinonasal epithelial cells. Int Forum Allergy Rhinol (2017) 0.75
The nature of the principal type 1 interferon-producing cells in human blood. Science (1999) 10.90
Mouse and human dendritic cell subtypes. Nat Rev Immunol (2002) 10.01
Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child (1986) 7.39
BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol (2000) 6.04
Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med (2000) 5.24
Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med (2000) 4.33
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med (2010) 4.17
Characterization of human blood dendritic cell subsets. Blood (2002) 3.97
Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J Exp Med (2002) 3.86
Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med (2010) 3.84
Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med (2010) 3.43
Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med (1986) 3.43
Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis (1991) 3.27
Mucosal dendritic cells. Annu Rev Immunol (2007) 3.26
The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med (2010) 3.20
Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol (2007) 3.19
Distinct differentiation potential of blood monocyte subsets in the lung. J Immunol (2007) 3.16
Blood monocyte subsets differentially give rise to CD103+ and CD103- pulmonary dendritic cell populations. J Immunol (2008) 3.04
Dendritic cell subsets in health and disease. Immunol Rev (2007) 2.45
Biology of lung dendritic cells at the origin of asthma. Immunity (2009) 2.43
Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology (2000) 2.28
Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. J Virol (2005) 2.16
Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol (1986) 2.09
Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 1.90
Differential response of dendritic cells to human metapneumovirus and respiratory syncytial virus. Am J Respir Cell Mol Biol (2005) 1.87
Replication-dependent potent IFN-alpha induction in human plasmacytoid dendritic cells by a single-stranded RNA virus. J Immunol (2004) 1.85
Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis (2001) 1.79
The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev (1996) 1.78
Plasmacytoid dendritic cell precursors/type I interferon-producing cells sense viral infection by Toll-like receptor (TLR) 7 and TLR9. Springer Semin Immunopathol (2004) 1.72
Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood (2007) 1.67
Identification and characterization of human pulmonary dendritic cells. Am J Respir Cell Mol Biol (2004) 1.66
Allergen-enhanced thrombomodulin (blood dendritic cell antigen 3, CD141) expression on dendritic cells is associated with a TH2-skewed immune response. J Allergy Clin Immunol (2008) 1.62
Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr Infect Dis J (2003) 1.62
NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol (2002) 1.55
Rapid dendritic cell recruitment to the bronchial mucosa of patients with atopic asthma in response to local allergen challenge. Thorax (2001) 1.47
Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections. J Infect Dis (2005) 1.46
Found in translation: the human equivalent of mouse CD8+ dendritic cells. J Exp Med (2010) 1.45
Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways. J Virol (2009) 1.34
Respiratory syncytial virus infection of monocyte-derived dendritic cells decreases their capacity to activate CD4 T cells. J Immunol (2005) 1.30
Different roles for human lung dendritic cell subsets in pulmonary immune defense mechanisms. Am J Respir Cell Mol Biol (2006) 1.30
Respiratory syncytial virus decreases the capacity of myeloid dendritic cells to induce interferon-gamma in naïve T cells. Immunology (2003) 1.30
Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol (2006) 1.28
Respiratory syncytial virus induces prostaglandin E2, IL-10 and IL-11 generation in antigen presenting cells. Clin Exp Immunol (2002) 1.25
Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. J Virol (2008) 1.22
Interactions of viruses with dendritic cells: a double-edged sword. J Exp Med (1997) 1.20
Defective regulation of immune responses in respiratory syncytial virus infection. J Immunol (1984) 1.20
Different effects of influenza virus, respiratory syncytial virus, and Sendai virus on human lymphocytes and macrophages. Infect Immun (1982) 1.19
A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo. Eur J Immunol (1999) 1.16
Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis (2008) 1.14
Differential recruitment of dendritic cells and monocytes to respiratory mucosal sites in children with influenza virus or respiratory syncytial virus infection. J Infect Dis (2008) 1.13
Monocyte-derived CD1a+ and CD1a- dendritic cell subsets differ in their cytokine production profiles, susceptibilities to transfection, and capacities to direct Th cell differentiation. J Immunol (2000) 1.13
Cross-talk between dendritic cells and natural killer cells in viral infection. Mol Immunol (2005) 1.11
Airway epithelial cells regulate the functional phenotype of locally differentiating dendritic cells: implications for the pathogenesis of infectious and allergic airway disease. J Immunol (2009) 1.11
RSV bronchiolitis and risk of wheeze and allergic sensitisation in the first year of life. Eur Respir J (2002) 1.09
Emerging role of dendritic cells in respiratory viral infection. J Mol Med (Berl) (2007) 1.08
Effect of aging on cytokine production in response to respiratory syncytial virus infection. J Infect Dis (2002) 1.06
Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity. Pediatr Res (2002) 1.06
Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection. Int Immunol (2007) 1.05
Lower levels of plasmacytoid dendritic cells in peripheral blood are associated with a diagnosis of asthma 6 yr after severe respiratory syncytial virus bronchiolitis. Pediatr Allergy Immunol (2008) 1.04
Soluble G protein of respiratory syncytial virus inhibits Toll-like receptor 3/4-mediated IFN-beta induction. Int Immunol (2008) 1.03
Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses. J Virol (2003) 1.00
Calcium requirement for syncytium formation in HEp-2 cells by respiratory syncytial virus. J Clin Microbiol (1988) 1.00
Differences in participation of innate and adaptive immunity to respiratory syncytial virus in adults and neonates. J Infect Dis (2003) 0.99
Differentiation and immune function of human dendritic cells following infection by respiratory syncytial virus. Clin Exp Immunol (2006) 0.99
Th1 or Th2 balance regulated by interaction between dendritic cells and NKT cells. Immunol Res (2007) 0.98
Photoexcitation of tryptophan groups induces reduction of two disulfide bonds in goat alpha-lactalbumin. Biochemistry (2002) 0.97
UV-B-induced inhibition of photosystem II electron transport studied by EPR and chlorophyll fluorescence. Impairment of donor and acceptor side components. Biochemistry (1996) 0.97
Respiratory syncytial virus infection induces matrix metalloproteinase-9 expression in epithelial cells. Arch Virol (2002) 0.96
Surfactant protein A binds to the fusion glycoprotein of respiratory syncytial virus and neutralizes virion infectivity. J Infect Dis (1999) 0.94
Infectious respiratory syncytial virus (RSV) effectively inhibits the proliferative T cell response to inactivated RSV in vitro. J Infect Dis (1992) 0.91
Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in the respiratory tracts of human infants following paramyxovirus infection. J Med Virol (2007) 0.90
Persistent of respiratory syncytial virus in human dendritic cells and influence of nitric oxide. Clin Exp Immunol (2007) 0.90
Severe respiratory syncytial virus infections and reduced interferon-gamma generation in vitro. Clin Exp Immunol (2004) 0.88
Interactions between epithelial cells and dendritic cells in airway immune responses: lessons from allergic airway disease. Allergy (2008) 0.87
Differential response of human naive and memory/effector T cells to dendritic cells infected by respiratory syncytial virus. Clin Exp Immunol (2007) 0.85
Human monocytes differentiate into macrophages under the influence of human KPB-M15 conditioned medium. J Immunol Methods (2005) 0.83
Cytokine production from peripheral blood mononuclear cells of mite allergen-sensitized atopic adults stimulated with respiratory syncytial virus and mite allergen. Int Arch Allergy Immunol (2008) 0.76
Ultraviolet irradiation selectively disrupts the gamma-aminobutyric acid/benzodiazepine receptor-linked chloride ionophore. Mol Pharmacol (1989) 0.76
Differential sensitivity of major types of opioid binding sites to U.V. irradiation. Neuropeptides (1984) 0.76
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis (2006) 5.53
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 5.22
Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science (2013) 4.60
Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science (2013) 3.90
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis (2011) 3.19
Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol (2007) 3.19
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis (2007) 3.02
Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science (2013) 2.95
Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol (2009) 2.71
Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A (2010) 2.69
Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine (2007) 2.68
Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol (2011) 2.53
The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol (2006) 2.43
A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol (2006) 2.39
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol (2011) 2.34
Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One (2010) 2.24
Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol (2003) 2.20
Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. J Infect Dis (2002) 2.19
Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice. Am J Respir Crit Care Med (2002) 2.17
Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog (2008) 2.00
The role of IFN in respiratory syncytial virus pathogenesis. J Immunol (2002) 1.95
Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol (2010) 1.89
Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol (2010) 1.81
A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One (2011) 1.81
A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis (2010) 1.79
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr (2007) 1.73
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One (2010) 1.71
Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. Vaccine (2006) 1.71
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology (2009) 1.58
NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol (2002) 1.55
Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. J Biol Chem (2002) 1.54
Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PLoS One (2010) 1.53
Respiratory syncytial virus infection in the absence of STAT 1 results in airway dysfunction, airway mucus, and augmented IL-17 levels. J Allergy Clin Immunol (2005) 1.52
Chimpanzee Adenovirus Vector Ebola Vaccine--Preliminary Report. N Engl J Med (2015) 1.51
Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities. J Virol (2009) 1.51
Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis (2013) 1.45
Subunit recombinant vaccine protects against monkeypox. J Immunol (2006) 1.44
A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis (2011) 1.42
Pathogenesis of respiratory syncytial virus infection in the murine model. Proc Am Thorac Soc (2005) 1.42
Lessons from failure--preparing for future HIV-1 vaccine efficacy trials. J Infect Dis (2005) 1.40
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine (2008) 1.39
Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol (2011) 1.39
Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J Virol (2010) 1.38
Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection. J Immunol (2004) 1.38
Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. J Clin Invest (2012) 1.37
RhoA signaling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphology. J Virol (2005) 1.36
Modified vaccinia Ankara: potential as an alternative smallpox vaccine. Clin Infect Dis (2004) 1.36
Role of plasma membrane lipid microdomains in respiratory syncytial virus filament formation. J Virol (2003) 1.33
Smallpox vaccines: Past, present, and future. J Allergy Clin Immunol (2006) 1.33
IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J Immunol (2003) 1.29
Respiratory syncytial virus in allergic lung inflammation increases Muc5ac and gob-5. Am J Respir Crit Care Med (2004) 1.27
Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J Acquir Immune Defic Syndr (2007) 1.25
DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J Infect Dis (2013) 1.24
Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus. Virology (2005) 1.23
Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. J Virol (2009) 1.21
Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J Virol (2004) 1.21
Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One (2010) 1.21
HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol (2011) 1.21
Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J Infect Dis (2004) 1.20
Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol (2010) 1.18
DNA vaccines: a safe and efficient platform technology for responding to emerging infectious diseases. Hum Vaccin (2009) 1.17
Neonatal CD8 T-cell hierarchy is distinct from adults and is influenced by intrinsic T cell properties in respiratory syncytial virus infected mice. PLoS Pathog (2011) 1.17
Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J Virol (2014) 1.15
Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J Virol (2004) 1.15
Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. Vaccine (2007) 1.14
Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial. PLoS One (2011) 1.13
The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nat Rev Immunol (2010) 1.10
Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes. J Acquir Immune Defic Syndr (2006) 1.07
Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies. J Virol (2006) 1.07
Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J Infect Dis (2013) 1.07
Responses against a subdominant CD8+ T cell epitope protect against immunopathology caused by a dominant epitope. J Immunol (2010) 1.06
Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4. J Virol (2004) 1.05
Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2. J Virol (2011) 1.04
Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol (2013) 1.01
A filovirus-unique region of Ebola virus nucleoprotein confers aberrant migration and mediates its incorporation into virions. J Virol (2008) 1.01
Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. Pediatr Infect Dis J (2004) 1.01
Relative dominance of epitope-specific CD8+ T cell responses in an F1 hybrid mouse model of respiratory syncytial virus infection. Virology (2007) 1.01
Cyclooxygenase inhibition augments allergic inflammation through CD4-dependent, STAT6-independent mechanisms. J Immunol (2005) 0.97
Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness. J Virol (2004) 0.96
The immune space: a concept and template for rationalizing vaccine development. AIDS Res Hum Retroviruses (2014) 0.92
Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. J Infect Dis (2011) 0.92
Evidence of prior exposure to human bocavirus as determined by a retrospective serological study of 404 serum samples from adults in the United States. Clin Vaccine Immunol (2009) 0.92
T Cell receptor clonotype influences epitope hierarchy in the CD8+ T cell response to respiratory syncytial virus infection. J Biol Chem (2010) 0.91
Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model. J Virol (2009) 0.90
Allergen-induced airway hyperresponsiveness mediated by cyclooxygenase inhibition is not dependent on 5-lipoxygenase or IL-5, but is IL-13 dependent. J Immunol (2005) 0.90
HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. PLoS Pathog (2013) 0.90
GM-CSF production allows the identification of immunoprevalent antigens recognized by human CD4+ T cells following smallpox vaccination. PLoS One (2011) 0.90
Treatment with anti-LFA-1 delays the CD8+ cytotoxic-T-lymphocyte response and viral clearance in mice with primary respiratory syncytial virus infection. J Virol (2004) 0.89
HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. J Clin Invest (2014) 0.88
Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein. J Leukoc Biol (2008) 0.87
Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA. J Immunol (2011) 0.86
The complex relationship between respiratory syncytial virus and allergy in lung disease. Viral Immunol (2003) 0.86
Respiratory syncytial virus and other pneumoviruses: a review of the international symposium--RSV 2003. Virus Res (2004) 0.85
IL-13 is associated with reduced illness and replication in primary respiratory syncytial virus infection in the mouse. Microbes Infect (2006) 0.84
Epitope-specific regulatory CD4 T cells reduce virus-induced illness while preserving CD8 T-cell effector function at the site of infection. J Virol (2010) 0.83
Subtypes of type I IFN differentially enhance cytokine expression by suboptimally stimulated CD4(+) T cells. Eur J Immunol (2013) 0.82
Lymph Node Activation by PET/CT Following Vaccination With Licensed Vaccines for Human Papillomaviruses. Clin Nucl Med (2017) 0.80